Episode 165
New Alzheimer's Drug Approval Expands Treatment Options — and Creates Coverage Questions
July 19, 202415m 1s
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Health Affairs' Jeff Byers welcomes Senior Editor Leslie Erdelack to the program to discuss FDA's recent approval of an Alzheimer's treatment drug, Lilly’s Kisunla, how private insurers and Medicare may cover the drug, and the emerging new class of drugs surrounding Alzheimer's treatment.
We announced the winner for our You're A Health Policy Wonk If... contest this week!
Check out our Request For Abstracts page for the April 2025 theme issue focusing on Food, Nutrition, and Health.
Related Articles:
- Approval of Newest Alzheimer’s Drug Will Accelerate New Era of Treatment by Peter Loftus and Joseph Walker (Wall Street Journal)
- Press Release: Lilly's Kisunla Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease
Topics
health policyhealth affairshealth inequitiesACAAffordable Care Actindividual mandateMedicareMedicaidCMSHHS